Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinical Manifestations and Risk Factors for Complications of Philadelphia Chromosome-Negative Myeloproliferative Neoplasms.

Asian Pacific journal of cancer prevention : APJCP - 1 Jan 2015

Duangnapasatit Boonlerd, Rattarittamrong Ekarat, Rattanathammethee Thanawat, Hantrakool Sasinee, Chai-Adisaksopha Chatree, Tantiworawit Adisak, Norasetthada Lalita

Abstract excerpt

BACKGROUND: Myeloproliferative neoplasms (MPNs) are clonal hematopoietic stem cell disorders characterized by proliferation of one or more myeloid lineages. Polycythemia vera (PV), essential thrombocythemia (ET) and primary myelofibrosis (PMF) are classical Philadelphia chromosome (Ph)-negative MPN that have a Janus Kinase 2 (JAK2) mutation, especially JAK2V617F in the majority of patients. The major...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Janus Kinase 2
Share to Leukemia

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Myeloproliferative Disorders

Share to Philadelphia Chromosome

Share to Polycythemia Vera

Share to Primary Myelofibrosis

Share to Thrombocythemia, Essential

Share to Thrombosis

Source

Identifiers

PMID: 26163633
DOI: 10.7314/apjcp.2015.16.12.5013

Genes

JAK2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical Manifestations and Risk Factors for Complications of Philadelphia Chromosome-Negative Myeloproliferative Neoplasms.PMID 26163633Read ↗

Current approaches to challenging scenarios in myeloproliferative neoplasms.Semantic proximity Read ↗

Myeloproliferative Neoplasms, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology.Semantic proximity Read ↗

[Clinical and epidemiological characteristics of the Philadelphia negative myeloproliferative neoplasms in Chile].Semantic proximity Read ↗

[Clinical and epidemiological characteristics of the Philadelphia negative myeloproliferative neoplasms in Chile].Semantic proximity Read ↗

Clinical features of patients with Philadelphia-negative myeloproliferative neoplasms complicated by portal hypertension.Semantic proximity Read ↗

Secondary acute myeloid leukemias arising from Philadelphia chromosome negative myeloproliferative neoplasms: pathogenesis, risk factors, and therapeutic strategies.Semantic proximity Read ↗

Diagnosis, risk stratification, and response evaluation in classical myeloproliferative neoplasms.Semantic proximity Read ↗

Thrombotic and bleeding complications in classical myeloproliferative neoplasms.Semantic proximity Read ↗

Clinical Features of 294 Turkish Patients with Chronic Myeloproliferative Neoplasms.Semantic proximity Read ↗

Evaluation of clinical and laboratory findings with JAK2 V617F mutation as an independent variable in essential thrombocytosis.Semantic proximity Read ↗

Clinical insights into the origins of thrombosis in myeloproliferative neoplasms.Semantic proximity Read ↗

Philadelphia Chromosome–Negative Myeloproliferative Disorders: Biology and TreatmentSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.